Global Covid-19 vaccine Market will be valued at approximately USD 25 billion in the year 2024. The growing government support for vaccine development and the increasing involvement of global organizations in the development of adequate vaccination facilities in endemic regions is anticipated to positively influence the sales of Coronavirus vaccine in the upcoming years. Moreover, the strong demand for coronavirus vaccine, the ongoing initiatives by governments to procure the vaccine and the waves of infection is likely to drive the market growth during the forecast period. Under the Patient Type segment, Covid-19 market for senior citizens is anticipated to witness the largest market share owing to the focus of the governments to vaccinate the vulnerable population, manufacturing of vaccines being outsourced and also manufacturers collaborating with hospitals and doctors to better understand their demand and meet their requirements will be pushing growth in the market for Covid-19 vaccine during the coming years.
Hospitals, followed by Clinics, Vaccination centers and Academic and research Institute will attain substantial market share as healthcare authorities and governments are trying their best to vaccinate the population to further avoid spread of coronavirus disease.
Among the regions, North America, followed by Europe and Asia Pacific, will experience remarkable growth owing to the second and third wave of spread of the virus, emergence of mutant viruses, presence of various leading global manufacturers in the region with companies ramping up their production capacity and growing number of coronavirus patients.
Scope of the Report
Key Target Audience
Hospitals, followed by Clinics, Vaccination centers and Academic and research Institute will attain substantial market share as healthcare authorities and governments are trying their best to vaccinate the population to further avoid spread of coronavirus disease.
Among the regions, North America, followed by Europe and Asia Pacific, will experience remarkable growth owing to the second and third wave of spread of the virus, emergence of mutant viruses, presence of various leading global manufacturers in the region with companies ramping up their production capacity and growing number of coronavirus patients.
Scope of the Report
- The report analyses Covid-19 vaccine market By Value.
- The report analyses Covid-19 vaccine Market By Product Type (Multivalent Vaccine, Monovalent vaccine).
- The report analyses Covid-19 vaccine Market By Patient Type (Paediatric, Adult, Senior Citizens).
- The report further Covid-19 vaccine market By End User (Hospitals, Clinics, Vaccination Centers, Academic and Research Institute, Others).
- The Covid-19 vaccine Market has been analysed By Region (North America, Europe, and Asia Pacific) and By Country (United States, Canada, Germany, France, United Kingdom, Switzerland, Russia, China, Japan, India).
- The key insights of the report have been presented through the frameworks of Major Mergers & Acquisitions, Technological Innovations, and Role of Manufacturers during COVID Pandemic. Also, the attractiveness of the market has been presented By Region, Product Type, Patient type and End User. Additionally, the major opportunities, trends, drivers and challenges of the industry has been analysed in the report.
- The companies analysed in the report include AstraZeneca Plc, Johnson & Johnson Inc, Novavax, BioNTech, Moderna, Glaxo Smith Kline Plc, CSL Ltd., Abbott Laboratories, Daiichi Sankyo Company Ltd, Astellas Pharma Inc.
- The report presents the analysis of Covid-19 vaccine market for the forecast period of 2025-2030.
Key Target Audience
- Covid-19 Vaccine Manufacturers
- Covid-19 vaccine Suppliers
- Hospitals, Vaccination Centers and Healthcare Units
- Consulting and Advisory Firms
- Investment Banks and Equity Firms
Table of Contents
1. Research Methodology and Executive Summary1.1 Research Methodology
1.2 Executive Summary
2. Strategic Recommendations
3. Covid-19 Vaccine Market: Product Outlook
4. Global Covid-19 Vaccine Market: Sizing and Forecast
4.1 Market Size, By Value, Year 2020-2030
5. Global Covid-19 Vaccine Market Segmentation - By Product Type, Patient Type, End User
5.1 Competitive Scenario of Global Covid-19 Vaccine Market: By Product Type
5.1.1 Multivalent vaccine - Market Size and Forecast (2020-2030)
5.1.2 Monovalent Vaccine - Market Size and Forecast (2020-2030)
5.2 Competitive Scenario of Global Covid-19 Vaccine Market: By Patient Type
5.2.1 Paediatric - Market Size and Forecast (2020-2030)
5.2.2 Adult - Market Size and Forecast (2020-2030)
5.2.3 Senior Citizens - Market Size and Forecast (2020-2030)
5.3 Competitive Scenario of Global Covid-19 Vaccine Market: By End User
5.3.1 Hospitals - Market Size and Forecast (2020-2030)
5.3.2 Clinics - Market Size and Forecast (2020-2030)
5.3.3 Vaccination centers - Market Size and Forecast (2020-2030)
5.3.4 Academic and research Centers - Market Size and Forecast (2020-2030)
5.3.5 Others - Market Size and Forecast (2020-2030)
6. Global Covid-19 Vaccine Market: Regional Analysis
6.1 Competitive Scenario of Global Covid-19 Vaccine Market: By Region
7. North America Covid-19 Vaccine Market: An Analysis (2020-2030)
7.1 North America Covid-19 Vaccine Market: Size and Forecast (2020-2030), By Value
7.2 North America Covid-19 Vaccine Market - Prominent Companies
7.3 Market Segmentation By Product Type (Multivalent Vaccine and Monovalent Vaccine)
7.4 Market Segmentation By Patient Type (Paediatric, Adult and Senior Citizens)
7.5 Market Segmentation By End User (Hospitals, Clinics, Vaccination Centers, Academic and Research Centers, Others)
7.6 North America Covid-19 Vaccine Market: Country Analysis
7.7 Market Opportunity Chart of North America Covid-19 Vaccine Market - By Country, By Value, 2030
7.8 Competitive Scenario of North America Covid-19 Vaccine Market: By Country
7.9 United States Covid-19 Vaccine Market: Size and Forecast (2020-2030), By Value
7.10 United States Covid-19 Vaccine Market Segmentation - By Product Type, By Patient Type, and By End User (2020-2030)
7.11 Canada Covid-19 Vaccine Market: Size and Forecast (2020-2030), By Value
7.12 Canada Covid-19 Vaccine MarketSegmentation - By Product Type, By Patient Type, and By End User (2020-2030)
8. Europe Covid-19 Vaccine Market: An Analysis (2020-2030)
8.1 Europe Covid-19 Vaccine Market: Size and Forecast (2020-2030), By Value
8.2 Europe Covid-19 Vaccine Market - Prominent Companies
8.3 Market Segmentation By Product Type (Multivalent Vaccine and Monovalent Vaccine)
8.4 Market Segmentation By Patient Type (Paediatric, Adult and Senior Citizens)
8.5 Market Segmentation By End User (Hospitals, Clinics, Vaccination Centers, Academic and Research Centers, Others)
8.6 Europe Covid-19 Vaccine Market: Country Analysis
8.7 Market Opportunity Chart Europe Covid-19 Vaccine Market - By Country, By Value, 2030
8.8 Competitive Scenario of Europe Covid-19 Vaccine Market: By Country
8.9 Germany Covid-19 Vaccine Market: Size and Forecast (2020-2030), By Value
8.10 Germany Covid-19 Vaccine Market Segmentation - By Product Type, By Patient Type, and By End User (2020-2030)
8.11 France Covid-19 Vaccine Market: Size and Forecast (2020-2030), By Value
8.12 France Covid-19 Vaccine MarketSegmentation - By Product Type, By Patient Type, and By End User (2020-2030)
8.13 United Kingdom Covid-19 Vaccine Market: Size and Forecast (2020-2030), By Value
8.14 United Kingdom Covid-19 Vaccine Market Segmentation - By Product Type, By Patient Type, and By End User (2020-2030)
8.15 Switzerland Covid-19 Vaccine Market: Size and Forecast (2020-2030), By Value
8.16 Switzerland Covid-19 Vaccine MarketSegmentation - By Product Type, By Patient Type, and By End User (2020-2030)
8.17 Russia Covid-19 Vaccine Market: Size and Forecast (2020-2030), By Value
8.18 Russia Covid-19 Vaccine MarketSegmentation - By Product Type, By Patient Type, and By End User (2020-2030)
9. Asia Pacific Covid-19 Vaccine Market: An Analysis (2020-2030)
9.1 Asia Pacific Covid-19 Vaccine Market: Size and Forecast (2020-2030), By Value
9.2 Asia Pacific Covid-19 Vaccine Market - Prominent Companies
9.3 Market Segmentation By Product Type (Multivalent Vaccine and Monovalent Vaccine)
9.4 Market Segmentation By Patient Type (Paediatric, Adult and Senior Citizens)
9.5 Market Segmentation By End User (Hospitals, Clinics, Vaccination Centers, Academic and Research Centers and Others)
9.6 Asia Pacific Covid-19 Vaccine Market: Country Analysis
9.7 Market Opportunity Chart of Asia Pacific Covid-19 Vaccine Market - By Country, By Value, 2030
9.8 Competitive Scenario of Asia Pacific Covid-19 Vaccine Market: By Country
9.9 China Covid-19 Vaccine Market: Size and Forecast (2020-2030), By Value
9.10 China Covid-19 Vaccine Market Segmentation -By Product Type, By Patient Type, and By End User (2020-2030)
9.11 Japan Covid-19 Vaccine Market: Size and Forecast (2020-2030), By Value
9.12 Japan Covid-19 Vaccine MarketSegmentation - By Product Type, By Patient Type, and By End User (2020-2030)
9.13 India Covid-19 Vaccine Market: Size and Forecast (2020-2030), By Value
9.14 India Covid-19 Vaccine Market Segmentation -By Product Type, By Patient Type, and By End User (2020-2030)
10. Global Covid-19 Vaccine Market Dynamics
10.1 Drivers
10.2 Trends
10.3 Challenge
11. Market Attractiveness
11.1 Market Attractiveness Chart of Covid-19 Vaccine MarketBy Product Type, 2030
11.2 Market Attractiveness Chart of Covid-19 Vaccine Market - By Patient Type, 2030
11.3 Market Attractiveness Chart of Covid-19 Vaccine Market - By End User, 2030
11.4 Market Attractiveness Chart of Covid-19 Vaccine Market - By Region, 2030
12. Competitive Landscape
13. Major Technological Innovations, M&A, Role of Manufacturers during Pandemic
14. Covid-19 Vaccines: Cost and Effectiveness
15. Regulatory compliance
16. Company Profiles (Business Description, Financial Analysis, Business Strategy)
16.1 AstraZeneca Plc
16.2 Johnson & Johnson
16.3 Novavax
16.4 BioNTech
16.5 Moderna
16.6 Glaxo Smith Kline
16.7 CSL Ltd.
16.8 Abbott Laboratories
16.9 Daiichi Sankyo Company Ltd.
16.10 Astellas Pharma Inc.List of Figures
Figure 1: Global Covid-19 Vaccine Market Size, By Value, 2020-2030 (USD Million)
Figure 2: Global Current Healthcare Expenditure Per Capita, 2015-2018 (In Numbers)
Figure 3: Global Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
Figure 4: Global Domestic Private Health Expenditure as % of Current Health Expenditure, 2015-2018 (In %)
Figure 5: Global Domestic Government Health Expenditure as % of GDP, 2015-2018 (In %)
Figure 6: Daily Covid-19 vaccine doses administered per 100 people , Feb 3, 2021 (In Millions)
Figure 7: Total no. of Covid-19 vaccination administered, Feb 3, 2021 (In Millions)
Figure 8: Share of people who received at least one dose of covid-19 vaccine, Feb 3, 2021 (In %)
Figure 9: Share of the population fully vaccinated against covid-19, Feb 3, 2021 (In %)
Figure 10: Global Number of people in extreme poverty due to covid-19, 2015-2020 (In Million)
Figure 11: Global Financial Stimulus Package Provided By Government, By Countries, 2020
Figure 12: Global Number of Intensive Care Beds, 2020 (In Numbers)
Figure 13: Global Number of Confirmed COVID19 Deaths, Feb 2021 (In Per Million People)
Figure 14: Global Covid-19 Vaccine Market, By Product Type, 2024, 2030
Figure 15: Global Covid-19 Vaccine Market, By Multivalent Vaccine, By Value (USD Million), 2020-2030
Figure 16: Global Covid-19 Vaccine Market, By Monovalent Vaccine, By Value (USD Million), 2020-2030
Figure 17: Global Covid-19 Vaccine Market, By Patient Type, 2024, 2030
Figure 18: Global Covid-19 Vaccine Market - By Paediatric, By Value (USD Million), 2020-2030
Figure 19: Global Covid-19 Vaccine Market - By Adult, By Value (USD Million), 2020-2030
Figure 20: Global Covid-19 Vaccine Market, By Senior Citizens, By Value (USD Million), 2020-2030
Figure 21: Global Covid-19 Vaccine Market, By End User, 2024, 2030
Figure 22: Global Covid-19 Vaccine Market, By Hospitals, By Value (USD Million), 2020-2030
Figure 23: Global Covid-19 Vaccine Market, By Clinics, By Value (USD Million), 2020-2030
Figure 24: Global Covid-19 Vaccine Market, By Vaccination Centers, By Value (USD Million), 2020-2030
Figure 25: Global Covid-19 Vaccine Market, By Academic and Research Centers, By Value (USD Million), 2020-2030
Figure 26: Global Covid-19 Vaccine Market, By Others, By Value (USD Million), 2020-2030
Figure 27: Global Covid-19 Vaccine Market, By Region, 2024, 2030
Figure 28: North America Covid-19 Vaccine Market Size, By Value, 2020-2030 (USD Million)
Figure 29: North America Current Healthcare Expenditure Per Capita, 2015-2018 (In Numbers)
Figure 30: North America Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
Figure 31: North America Domestic Private Health Expenditure as % of Current Health Expenditure, 2015-2018 (In %)
Figure 32: North America Domestic Government Health Expenditure as % of GDP, 2015-2018 (In %)
Figure 33: North America Number of Intensive Care Beds, 2020 (In Numbers
Figure 34: North America Number of Confirmed COVID19 Deaths, Feb 2021 (In Per Million People)
Figure 35: North America Covid-19 Vaccine Market, By Product, By Value (USD Million), 2020-2030
Figure 36: North America Covid-19 Vaccine Market, By Patient, By Value (USD Million), 2020-2030
Figure 37: North America Covid-19 Vaccine Market, By End user, By Value (USD Million), 2020-2030
Figure 38: Market Opportunity Chart of North America Covid-19 Vaccine Market - By Country, By Value, 2030
Figure 39: North America Covid-19 Vaccine Market, By Country, 2024, 2030
Figure 40: United State Covid-19 Vaccine Market Size, By Value, 2020-2030 (USD Million)
Figure 41: United State Healthcare Expenditure Per Capita, 2015-2018 (In Numbers)
Figure 42: United State Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
Figure 43: United State Domestic Private Health Expenditure as % of Current Health Expenditure, 2015-2018 (In %)
Figure 44: United State Domestic Government Health Expenditure as % of GDP, 2015-2018 (In %)
Figure 45: United Kingdom Covid-19 Vaccine Market, By Product, By Value (USD Million), 2020-2030
Figure 46: United State Covid-19 Vaccine Market, By Patient, By Value (USD Million), 2020-2030
Figure 47: United State Covid-19 Vaccine Market, By End user, By Value (USD Million), 2020-2030
Figure 48: Canada Covid-19 Vaccine Market Size, By Value, 2020-2030 (USD Million)
Figure 49: Canada Current Healthcare Expenditure Per Capita, 2015-2018 (In Numbers)
Figure 50: Canada Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
Figure 51: Canada Domestic Private Health Expenditure as % of Current Health Expenditure, 2015-2018 (In %)
Figure 52: Canada Domestic Government Health Expenditure as % of GDP, 2015-2018 (In %)
Figure 53: Canada Covid-19 Vaccine Market, By Product, By Value (USD Million), 2020-2030
Figure 54: Canada Covid-19 Vaccine Market, By Patient, By Value (USD Million), 2020-2030
Figure 55: Canada Covid-19 Vaccine Market, By End user, By Value (USD Million), 2020-2030
Figure 56: Europe Covid-19 Vaccine Market Size, By Value, 2020-2030 (USD Million)
Figure 57: Europe Current Healthcare Expenditure Per Capita, 2015-2018 (In Numbers)
Figure 58: Europe Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
Figure 59: Europe Domestic Private Health Expenditure as % of Current Health Expenditure, 2015-2018 (In %)
Figure 60: Europe Domestic Government Health Expenditure as % of GDP, 2015-2018 (In %)
Figure 61: Europe Number of Intensive Care Beds, 2020 (In Numbers)
Figure 62: Europe Number of Confirmed COVID19 Deaths, Feb 2021 (In Per Million People)
Figure 63: Europe Covid-19 Vaccine Market, By Product, By Value (USD Million), 2020-2030
Figure 64: Europe Covid-19 Vaccine Market, By Patient, By Value (USD Million), 2020-2030
Figure 65: Europe Covid-19 Vaccine Market, By End user, By Value (USD Million), 2020-2030
Figure 66: Market Opportunity Chart of Europe Covid-19 Vaccine Market - By Country, By Value, 2030
Figure 67: Europe Covid-19 Vaccine Market, By Country, 2024, 2030
Figure 68: Germany Covid-19 Vaccine Market Size, By Value, 2020-2030 (USD Million)
Figure 69: Germany Current Healthcare Expenditure Per Capita, 2015-2018 (In Numbers)
Figure 70: Germany Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
Figure 71: Germany Domestic Private Health Expenditure as % of Current Health
Figure 72: Germany Domestic Government Health Expenditure as % of GDP, 2015-2018 (In %)
Figure 73: Germany Covid-19 Vaccine Market, By Product, By Value (USD Million), 2020-2030
Figure 74: Germany Covid-19 Vaccine Market, By Patient, By Value (USD Million), 2020-2030
Figure 75: Germany Covid-19 Vaccine Market, By End user, By Value (USD Million), 2020-2030
Figure 76: France Covid-19 Vaccine Market Size, By Value, 2020-2030 (USD Million)
Figure 77: France Current Healthcare Expenditure Per Capita, 2015-2018 (In Numbers)
Figure 78: France Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
Figure 79: France Domestic Private Health Expenditure as % of Current Health Expenditure, 2015-2018 (In %)
Figure 80: France Domestic Government Health Expenditure as % of GDP, 2015-2018 (In %)
Figure 81: France Covid-19 Vaccine Market, By Product, By Value (USD Million), 2020-2030
Figure 82: France Covid-19 Vaccine Market, By Patient, By Value (USD Million), 2020-2030
Figure 83: France Covid-19 Vaccine Market, By End user, By Value (USD Million), 2020-2030
Figure 84: United Kingdom Covid-19 Vaccine Market Size, By Value, 2020-2030 (USD Million)
Figure 85: United Kingdom Current Healthcare Expenditure Per Capita, 2015-2018 (In Numbers)
Figure 86: United Kingdom Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
Figure 87: United Kingdom Domestic Private Health Expenditure as % of Current Health Expenditure, 2015-2018 (In %)
Figure 88: United Kingdom Domestic Government Health Expenditure as % of GDP, 2015-2018 (In %)
Figure 89: United Kingdom Covid-19 Vaccine Market, By Product, By Value (USD Million), 2020-2030
Figure 90: United Kingdom Covid-19 Vaccine Market, By Patient, By Value (USD Million), 2020-2030
Figure 91: United Kingdom Covid-19 Vaccine Market, By End user, By Value (USD Million), 2020-2030
Figure 92: Switzerland Covid-19 Vaccine Market Size, By Value, 2020-2030 (USD Million)
Figure 93: Switzerland Current Healthcare Expenditure Per Capita, 2015-2018 (In Numbers)
Figure 94: Switzerland Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
Figure 95: Switzerland Domestic Private Health Expenditure as % of Current Health Expenditure, 2015-2018 (In %)
Figure 96: Switzerland Domestic Government Health Expenditure as % of GDP, 2015-2018 (In %)
Figure 97: Switzerland Covid-19 Vaccine Market, By Product, By Value (USD Million), 2020-2030
Figure 98: Switzerland Covid-19 Vaccine Market, By Patient, By Value (USD Million), 2020-2030
Figure 99: Switzerland Covid-19 Vaccine Market, By End user, By Value (USD Million), 2020-2030
Figure 100: Russia Covid-19 Vaccine Market Size, By Value, 2020-2030 (USD Million)
Figure 101: Russia Current Healthcare Expenditure Per Capita, 2015-2018 (In Numbers)
Figure 102: Russia Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
Figure 103: Russia Domestic Private Health Expenditure as % of Current Health Expenditure, 2015-2018 (In %)
Figure 104: Russia Domestic Government Health Expenditure as % of GDP, 2015-2018 (In %)
Figure 105: Russia Covid-19 Vaccine Market, By Product, By Value (USD Million), 2020-2030
Figure 106: Russia Covid-19 Vaccine Market, By Patient, By Value (USD Million), 2020-2030
Figure 107: Russia Covid-19 Vaccine Market, By End user, By Value (USD Million), 2020-2030
Figure 108: Asia Pacific Covid-19 Vaccine Market Size, By Value, 2020-2030 (USD Million)
Figure 109: Asia Pacific Current Healthcare Expenditure Per Capita, 2015-2018 (In Numbers)
Figure 110: Asia Pacific Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
Figure 111: Asia Pacific Domestic Private Health Expenditure as % of Current Health Expenditure, 2015-2018 (In %)
Figure 112: Asia Pacific Domestic Government Health Expenditure as % of GDP, 2015-2018 (In %)
Figure 113: Asia Number of Intensive Care Beds, 2020 (In Numbers)
Figure 114: Asia Number of Confirmed COVID19 Deaths, Feb 2021 (In Per Million People)
Figure 115: Asia Pacific Covid-19 Vaccine Market, By Product, By Value (USD Million), 2020-2030
Figure 116: Asia Pacific Covid-19 Vaccine Market, By Patient, By Value (USD Million), 2020-2030
Figure 117: Asia Pacific Covid-19 Vaccine Market, By End user, By Value (USD Million), 2020-2030
Figure 118: Market Opportunity Chart of Asia Pacific Covid-19 Vaccine Market - By Country, By Value, 2030
Figure 119: Asia Pacific Covid-19 Vaccine Market, By Country, 2024, 2030
Figure 120: China Covid-19 Vaccine Market Size, By Value, 2020-2030 (USD Million)
Figure 121: China Current Healthcare Expenditure Per Capita, 2015-2018 (In Numbers)
Figure 122: China Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
Figure 123: China Domestic Private Health Expenditure as % of Current Health Expenditure, 2015-2018 (In %)
Figure 124: China Domestic Government Health Expenditure as % of GDP, 2015-2018 (In %)
Figure 125: United Kingdom Covid-19 Vaccine Market, By Product, By Value (USD Million), 2020-2030
Figure 126: United Kingdom Covid-19 Vaccine Market, By Patient, By Value (USD Million), 2020-2030
Figure 127: United Kingdom Covid-19 Vaccine Market, By End user, By Value (USD Million), 2020-2030
Figure 128: Japan Covid-19 Vaccine Market Size, By Value, 2020-2030 (USD Million)
Figure 129: Japan Current Healthcare Expenditure Per Capita, 2015-2018 (In Numbers)
Figure 130: Japan Current Healthcare Expenditure as percentage of GDP, 2015-2018 (In %)
Figure 131: Japan Domestic Private Health Expenditure as % of Current Health Expenditure, 2015-2018 (In %)
Figure 132: Japan Domestic Government Health Expenditure as % of GDP, 2015-2018 (In %)
Figure 133: Japan Covid-19 Vaccine Market, By Product, By Value (USD Million), 2020-2030
Figure 134: Japan Covid-19 Vaccine Market, By Patient, By Value (USD Million), 2020-2030
Figure 135: Japan Covid-19 Vaccine Market, By End user, By Value (USD Million), 2020-2030
Figure 136: India Covid-19 Vaccine Market Size, By Value, 2020-2030 (USD Million)
Figure 137: India Current Healthcare Expenditure Per Capita, 2015-2018 (In Numbers)
Figure 138: India Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
Figure 139: India Domestic Private Health Expenditure as % of Current Health Expenditure, 2015-2018 (In %)
Figure 140: India Domestic Government Health Expenditure as % of GDP, 2015-2018 (In %)
Figure 141: India Covid-19 Vaccine Market, By Product, By Value (USD Million), 2020-2030
Figure 142: India Covid-19 Vaccine Market, By Patient, By Value (USD Million), 2020-2030
Figure 143: IndiaCovid-19 Vaccine Market, By End user, By Value (USD Million), 2020-2030
Figure 144: Market Attractiveness Chart of Global Covid-19 Vaccine Market - By Product, 2030
Figure 145: Market Attractiveness Chart of Global Covid-19 Vaccine Market - By Patient, 2030
Figure 146: Market Attractiveness of Global Covid-19 Vaccine Market - By End User, 2025
Figure 147: Market Attractiveness Chart of Global Covid-19 Vaccine Market - By Region, 2030
Figure 148: Astra Zeneca Plc Corporation Revenue, 2015-2019 (In USD Million)
Figure 149: Astra Zeneca Plc Revenue, By Business Segment, 2018 (In %)
Figure 150: Astra Zeneca Plc Revenue, By Business Segment, 2019 (In %)
Figure 151: Astra Zeneca Plc Net Revenue, By Region, 2018 (In %)
Figure 152: Astra Zeneca Net Revenue, By Region, 2019 (In %)
Figure 153: Johnson & Johnson Inc. Revenue, 2015-2019 (In USD Million)
Figure 154: Johnson & Johnson Inc. Net Revenue, By Business Segment, 2018 (In %)
Figure 155: Johnson & Johnson Inc. Net Revenue, By Business Segment, 2019 (In %)
Figure 156: Johnson & Johnson Inc. Net Revenue, By Region, 2018 (In %)
Figure 157: Johnson & Johnson Inc. Net Revenue, By Region, 2019 (In %)
Figure 158: BioNTech Revenue, 2017-2019 (In USD Million)
Figure 159: BioNTech Net Sales, By Business Segment, 2018 (In %)
Figure 160: BioNTech Net Sales, By Business Segment, 2019 (In %)
Figure 161: Moderna Corporation Revenue, 2016-2019 (In USD Million)
Figure 162: Glaxo Smith Kline Plc Revenue, 2015-2019 (In USD Million)
Figure 163: Glaxo Smith Kline Plc Net Sales, By Business Segment, 2019 (In %)
Figure 164: Glaxo Smith Kline Plc Net Sales, By Business Segment, 2020 (In %)
Figure 165: Glaxo Smith Kline Plc Net Revenue, By Region, 2019 (In %)
Figure 166: Glaxo Smith Kline Plc Net Revenue, By Region, 2020 (In %)
Figure 167: CSL Ltd. Revenue, 2015-2020 (In USD Million)
Figure 168: CSL Ltd. Net Sales, By Business Segment, 2019 (In %)
Figure 169: CSL Ltd. Net Sales, By Business Segment, 2020 (In %)
Figure 170: CSL Ltd. Net Revenue, By Region, 2019 (In %)
Figure 171: CSL Ltd. Net Revenue, By Region, 2020 (In %)
Figure 172: Abbott Laboratories Revenue, 2015-2019 (In USD Million)
Figure 173: Abbott Laboratories Net Sales, By Business Segment, 2018 (In %)s
Figure 174: Abbott Laboratories Net Sales, By Business Segment, 2019 (In %)
Figure 175: Abbott Laboratories Net Revenue, By Region, 2018 (In %)
Figure 176: Abbott Laboratories Net Revenue, By Region, 2019 (In %)
Figure 177: Daiichi Sankyo Company Ltd. Revenue, 2015-2019 (In USD Million)
Figure 178: Daiichi Sankyo Plc Net Revenue, By Region, 2018,2019 (In %)
Figure 179: Astellas Pharma Inc. Revenue, 2015-2019 (In USD Million)
Figure 180: Astellas Pharma Inc. Net Sales, By Business Segment, 2018 (In %)
Figure 181: Astellas Pharma Inc. Net Sales, By Business Segment, 2019 (In %)
Figure 182: Astellas Pharma Inc. Net Revenue, By Region, 2018 (In %)
Figure 183: Astellas Pharma Inc. Net Revenue, By Region, 2019 (In %)
Companies Mentioned
- AstraZeneca Plc
- Johnson & Johnson Inc
- Novavax
- BioNTech
- Moderna
- Glaxo Smith Kline Plc
- CSL Ltd.
- Abbott Laboratories
- Daiichi Sankyo Company Ltd
- Astellas Pharma Inc.
